| Literature DB >> 33789036 |
Seung Hun Lee1, Jong Woo Kim2, Hyun-Ki Yoon2, Jung-Min Koh1, Chan Soo Shin3, Sang Wan Kim3,4, Jung Hee Kim3.
Abstract
BACKGROUND: Guidelines by the Endocrine Society Guideline on bypassing adrenal vein sampling (AVS) in patients <35 years old with marked primary aldosteronism (PA) (hypokalemia and elevated plasma aldosterone concentration [PAC]) and a unilateral lesion on computed tomography (CT) are based on limited number of studies. We aimed to determine the accuracy of CT in PA patients according to age.Entities:
Keywords: Aldosterone; Hyperaldosteronism; Hypokalemia
Mesh:
Substances:
Year: 2021 PMID: 33789036 PMCID: PMC8090455 DOI: 10.3803/EnM.2020.901
Source DB: PubMed Journal: Endocrinol Metab (Seoul) ISSN: 2093-596X
Baseline Characteristics of Patients Categorized by CT Findings (n=466)
| Variable | Total ( | Unilateral lesion ( | Bilateral normal ( | Bilateral lesion ( | |
|---|---|---|---|---|---|
| Age, yr | 51.0 (43.0–59.0) | 51.0 (43.5–59.0) | 47.0 (36.0–60.5) | 58.0 (51.0–64.0)[ | 0.003 |
| Female sex | 231 (49.6) | 189 (50.8) | 28 (50.9) | 14 (35.9) | 0.204 |
| Height, cm | 163.7 (157.6–170.0) | 163.3 (157.4–169.8) | 163.3 (156.2–170.9) | 167.6 (160.2–172.4) | 0.145 |
| Weight, kg | 67.4 (57.9–76.5) | 67.1 (57.3–76.1) | 66.0 (57.2–75.8) | 71.5 (64.5–80.1) | 0.077 |
| BMI, kg/m2 | 25.2 (22.7–27.3) | 25.2 (22.6–27.2) | 24.6 (22.3–26.7) | 25.9 (24.1–28.0) | 0.122 |
| Systolic BP, mm Hg | 142.0 (131.0–156.0) | 142.0 (132.0–155.0) | 150.0 (131.5–160.0) | 135.0 (125.5–153.5) | 0.082 |
| Diastolic BP, mm Hg | 90.0 (81.0–98.0) | 90.0 (81.0–97.0) | 91.0 (81.0–100.0) | 87.0 (77.5–97.0) | 0.262 |
| Antihypertensive drug, DDD | 2.0 (1.0–3.4) | 2.0 (1.0–3.5) | 1.0 (0.0–2.7)[ | 2.0 (1.0–3.5) | 0.039 |
| eGFR, mL/min/1.73 m2 | 88.3 (75.2–104.5) | 88.0 (75.8–103.5) | 90.1 (74.8–107.3) | 84.7 (73.5–110.2) | 0.838 |
| Serum potassium, mEq/L | 3.4 (3.0–4.0) | 3.3 (2.9–3.9) | 3.9 (3.5–4.2)[ | 3.6 (3.0; 4.2) | <0.001 |
| Hypokalemia | 228 (51.1) | 207 (55.6) | 12 (21.8)[ | 19 (48.7)[ | <0.001 |
| PAC, ng/dL | 30.5 (23.4–45.2) | 31.3 (24.1–47.2) | 26.3 (19.7–34.0)[ | 28.9 (21.9;41.9) | 0.001 |
| PRA, ng/mL/hr | 0.2 (0.1–0.4) | 0.2 (0.1–0.4) | 0.2 (0.1–0.5) | 0.2 (0.2–0.3) | 0.321 |
| ARR, ng/dL per ng/mL/hr | 146.5 (75.3–300.0) | 163.0 (76.2–320.5) | 96.0 (57.9–192.6)[ | 130.0 (91.0–239.2) | 0.012 |
| Nodule size on CT, cm | 1.5 (1.1–1.8) | 1.5 (1.1–1.8) | NA | 1.5 (1.1–1.8) | 0.182 |
Values are expressed as median (interquartile range) or number (%). α<0.017 was considered to be statistically significant after post hoc Bonferroni correction for multiple testing (α=0.05/3=0.0167).
α<0.017 unilateral lesion vs. bilateral normal;
α<0.017 unilateral lesion vs. bilateral lesion;
α<0.017 bilateral normal vs. bilateral lesion.
CT, computed tomography; BMI, body mass index; BP, blood pressure; DDD, defined daily dose; eGFR, estimated glomerular filtration rate; PAC, plasma aldosterone concentration; PRA, plasma renin activity; ARR, aldosterone-to-renin ratio; NA, not applicable.
Diagnostic Concordance Rate between CT and AVS Findings in Patients with PA (n=466)
| CT findings | AVS findings | Concordance of CT findings | Prevalence of unilateral PA on AVS | ||
|---|---|---|---|---|---|
|
| |||||
| Unilateral | Bilateral | ||||
|
| |||||
| Right | Left | ||||
| Unilateral lesion ( | 66.7 (248/372) | 71.8 (267/372) | |||
| Right ( | 97 | 8 | 35 | ||
| Left ( | 11 | 151 | 70 | ||
|
| |||||
| Bilateral ( | |||||
| Normal ( | 11 | 8 | 36 | 65.5 (36/55) | 34.5 (19/55) |
| Lesion ( | 10 | 13 | 16 | 41.0 (16/39) | 59.0 (23/39) |
|
| |||||
| Overall | 64.4 (300/466) | 66.3 (309/466) | |||
Values are expressed as percentage (number/total number).
CT, computed tomography; AVS, adrenal vein sampling; PA, primary aldosteronism.
Clinical Findings According to Diagnostic Concordance Rate between CT and Adrenal Vein Sampling Findings in Primary Aldosteronism Patients with Unilateral Lesion by CT (n=372)
| Variable | Concordance ( | Discordance ( | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| OR (95% CI) | OR (95% CI) | ||||||
| Age, yr | 49.0 (42.0–57.0) | 53.0 (46.0–60.0) | 0.002 | 0.971 (0.950–0.991) | <0.001 | 0.973 (0.948–0.998) | 0.035 |
|
| |||||||
| Female sex | 135 (54.4) | 54 (43.5) | 0.061 | 1.549 (1.003–2.391) | 0.048 | 1.197 (0.704–2.033) | 0.507 |
|
| |||||||
| Height, cm | 163.2 (157.4–169.0) | 163.7 (157.7–170.3) | 0.455 | NA | NA | ||
|
| |||||||
| Weight, kg | 65.2 (56.4–73.8) | 71.0 (62.5–80.1) | <0.001 | NA | NA | ||
|
| |||||||
| BMI, kg/m2 | 24.3 (22.2–26.7) | 26.3 (23.6–28.8) | <0.001 | 0.876 (0.825–0.931) | <0.001 | 0.901 (0.838–0.968) | 0.004 |
|
| |||||||
| Systolic BP, mm Hg | 143.5 (131.5–156.5) | 140.0 (132.0–152.5) | 0.258 | 1.004 (0.993–1.016) | 0.483 | NA | |
|
| |||||||
| Diastolic BP, mm Hg | 90.0 (82.0–99.0) | 88.0 (81.0–94.0) | 0.049 | 1.017 (0.999–1.035) | 0.067 | NA | |
|
| |||||||
| Anti-hypertensive drug, DDD | 2.0 (1.0–3.6) | 2.0 (0.7–3.2) | 0.062 | 1.000 (0.998–1.001) | 0.609 | NA | |
|
| |||||||
| eGFR, mL/min/1.73 m2 | 73.7 (58.7–92.2) | 72.9 (61.7–89.5) | 0.863 | 0.977 (0.991–1.009) | 0.977 | NA | |
|
| |||||||
| Serum potassium, mEq/L | 3.1 (2.8–3.5) | 3.9 (3.5–4.1) | <0.001 | 0.164 (0.104–0.259) | <0.001 | 0.258 (0.159–0420) | <0.001 |
|
| |||||||
| Hypokalemia | 176 (71.0) | 31 (25.0) | <0.001 | 7.333 (4.491–11.974) | <0.001 | NA | |
|
| |||||||
| PAC, ng/dL | 37.3 (27.4–55.5) | 26.1 (20.9–31.9) | <0.001 | 1.043 (1.026–1.059) | <0.001 | 1.011 (0.996–1.026) | 0.145 |
|
| |||||||
| PRA, ng/mL/hr | 0.2 (0.1–0.3) | 0.3 (0.2–0.5) | <0.001 | 0.833 (0.616–1.128) | 0.237 | ||
|
| |||||||
| ARR, ng/dL per ng/mL/hr | 234.5 (115.8–399.5) | 85.2 (51.0–156.9) | <0.001 | 1.006 (1.004–1.007) | <0.001 | 1.003 (1.001–1.005) | 0.002 |
|
| |||||||
| Nodule size on CT, cm | 1.5 (1.2–1.9) | 1.3 (1.0–1.8) | 0.011 | 1.124 (0.825–1.531) | 0.458 | NA | |
Values are expressed as median (interquartile range) or number (%).
CT, computed tomography; OR, odds ratio; CI, confidence interval; NA, not applicable; BMI, body mass index; BP, blood pressure; DDD, defined daily dose; eGFR, estimated glomerular filtration rate; PAC, plasma aldosterone concentration; PRA, plasma renin activity; ARR, aldosterone-to-renin ratio.
Diagnostic Concordance Rate between CT and AVS Findings in Patients with Marked PA (e.g., Hypokalemia and Plasma Aldosterone Concentration >15.9 ng/dL) and Unilateral Lesion on CT (n=198), Stratified by Age
| Variable | Total ( | Age, yr (<35, 35–39, 40–49, ≥50) | Age, yr (<50, ≥50) | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
| ||||||||
| <35 ( | 35–39 ( | 40–49 ( | ≥50 ( | <50 ( | ≥50 ( | ||||
| Unilateral PA on AVS | 0.283 | 0.081 | |||||||
| Ipsilateral lesion on CT | 169 (85.4) | 11 (84.6) | 20 (100.0) | 59 (89.4) | 79 (79.8) | 90 (90.9) | 79 (79.8) | ||
| Contralateral lesion on CT | 6 (3.0) | 0 | 0 | 2 (3.0) | 4 (4.0) | 2 (2.0) | 4 (4.0) | ||
|
| |||||||||
| Bilateral PA on AVS | 23 (11.6) | 2 (15.4) | 0 | 5 (7.6) | 16 (16.2) | 7 (7.1) | 16 (16.2) | ||
|
| |||||||||
| Concordance between CT and AVS | 0.061 | 0.044 | |||||||
| Concordance | 169 (85.4) | 11 (84.6) | 20 (100.0) | 59 (89.4) | 79 (79.8) | 90 (90.9) | 79 (79.8) | ||
| Discordance | 29 (14.6) | 2 (15.4) | 0 | 7 (10.6) | 20 (20.2) | 9 (9.1) | 20 (20.2) | ||
Values are expressed as number (%).
CT, computed tomography; AVS, adrenal vein sampling; PA, primary aldosteronism.
Fig. 1Receiver-operating characteristic (ROC) curve analyses for concordance of diagnosis between computed tomography (CT) and adrenal vein sampling findings for primary aldosteronism patients with unilateral lesion on CT. (A) Age, (B) K level, (C) plasma aldosterone concentration (PAC), and (D) tumor size. AUC, area under the ROC curve; CI, confidence interval.
Diagnostic Concordance Rate between CT and AVS Findings in Patients with Hypokalemia, Plasma Aldosterone Concentration >30.0 ng/dL, and Unilateral Lesion on CT (n=136), Stratified by Age
| Variable | Total ( | Age, yr (<35, 35–39, 40–49, ≥50) | Age, yr (<50, ≥50) | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
| ||||||||
| < 35 ( | 35–39 ( | 40–49 ( | ≥50 ( | <50 ( | ≥50 ( | ||||
| Unilateral PA on AVS | 0.658 | 0.773 | |||||||
| Ipsilateral lesion on CT | 125 (89.9) | 9 (81.8) | 12 (100.0) | 47 (92.2) | 57 (87.7) | 68 (91.9) | 57 (87.7) | ||
| Contralateral lesion on CT | 2 (1.4) | 0 | 0 | 1 (2.0) | 1 (1.5) | 1 (1.4) | 1 (1.5) | ||
|
| |||||||||
| Bilateral PA on AVS | 12 (8.6) | 2 (18.2) | 0 | 3 (5.9) | 7 (10.8) | 5 (6.8) | 7 (10.8) | ||
|
| |||||||||
| Concordance between CT and AVS | 0.419 | 0.590 | |||||||
| Concordance | 125 (89.9) | 9 (81.8) | 12 (100.0) | 47 (92.2) | 57 (87.7) | 68 (91.9) | 57 (87.7) | ||
| Discordance | 14 (10.1) | 2 (18.2) | 0 | 4 (7.8) | 8 (12.3) | 6 (8.1) | 8 (12.3) | ||
Values are expressed as number (%).
CT, computed tomography; AVS, adrenal vein sampling; PA, primary aldosteronism.
Comparison of Clinical Findings in PA Patients aged <40, 40–49, and ≥50 Years with Marked PA (e.g., Hypokalemia and PAC >15.9 ng/dL) and Unilateral Adrenal Lesion on CT (n=198)
| Variable | Age, yr (<35, 35–39, 40–49, ≥50) | Age, yr (<50, ≥50) | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| <35 ( | 35–39 ( | 40–49 ( | ≥50 ( | <50 ( | ≥50 ( | |||
| Age, yr | 33.0 (31.0–33.0) | 38.0[ | 45.0 (43.0–47.0) | 58.0[ | <0.001 | 43.0 (38.0–46.0) | 58.0 (53.0–63.0) | <0.001 |
|
| ||||||||
| Female sex | 10 (76.9) | 8 (40.0) | 33 (50.0) | 52 (52.5) | 0.212 | 51 (51.5) | 52 (52.5) | >0.999 |
|
| ||||||||
| Height, cm | 166.7 (163.0–169.0) | 168.1 (164.0–172.9) | 165.2 (159.6–172.0) | 161.0 (154.3–165.5) | <0.001 | 166.7 (161.0–171.1) | 161.0 (154.3–165.5) | <0.001 |
|
| ||||||||
| Weight, kg | 58.0 (53.4–65.4) | 68.5[ | 66.2 (57.6–74.8) | 65.3 (56.3–73.1) | 0.152 | 66.0 (57.5–74.8) | 65.3 (56.3–73.1) | 0.294 |
|
| ||||||||
| BMI, kg/m2 | 21.2 (19.7–25.9) | 23.6 (22.3–27.5) | 24.5 (21.9–25.8) | 24.5 (22.7–26.8) | 0.129 | 24.0 (21.7–26.1) | 24.5 (22.7–26.8) | 0.191 |
|
| ||||||||
| Systolic BP, mm Hg | 142.0 (123.0–146.0) | 150.0 (131.0–162.5) | 146.0 (139.0–160.0) | 140.0 (130.5–155.0) | 0.055 | 145.0 (137.5–160.0) | 140.0 (130.5–155.0) | 0.033 |
|
| ||||||||
| Diastolic BP, mm Hg | 93.0 (84.0–108.0) | 98.0 (82.5–109.5) | 95.5 (90.0–101.0) | 89.0 (80.0–95.0) | <0.001 | 95.0 (89.0–104.5) | 89.0 (80.0–95.0) | <0.001 |
|
| ||||||||
| Anti-hypertensive drugs, DDD | 1.0 (0.0–3.0) | 2.0 (1.2–3.1) | 2.3 (1.0–3.5) | 3.0 (1.7–4.0) | 0.043 | 2.0 (1.0–3.3) | 3.0 (1.7–4.0) | 0.009 |
|
| ||||||||
| eGFR, mL/min/1.73 m2 | 94.4 (90.1–103.2) | 93.0 (76.5–116.0) | 91.4 (77.5–110.2) | 81.5 (66.1–95.4) | 0.005 | 92.4 (77.7–111.2) | 81.5 (66.1–95.4) | <0.001 |
|
| ||||||||
| Serum potassium, mEq/L | 2.8 (2.6–3.0) | 3.1[ | 2.9 (2.7–3.1) | 3.0 (2.7–3.2) | 0.074 | 2.9 (2.7–3.1) | 3.0 (2.7–3.2) | 0.465 |
|
| ||||||||
| PAC, ng/dL | 51.2 (40.5–76.4) | 48.1 (23.6–58.5) | 46.8 (31.4–69.9) | 37.5 (28.1–48.8) | 0.009 | 48.5 (30.5–68.0) | 37.5 (28.1–48.8) | 0.003 |
|
| ||||||||
| PRA, ng/mL/hr | 0.3 (0.1–0.3) | 0.1 (0.1–0.3) | 0.2 (0.1–0.3) | 0.1 (0.1–0.2) | 0.305 | 0.2 (0.1–0.3) | 0.1 (0.1–0.2) | 0.153 |
|
| ||||||||
| ARR, ng/dL per ng/mL/hr | 238.8 (135.0–447.5) | 272.5 (99.2–576.0) | 268.5 (129.2–519.0) | 236.0 (141.3–395.5) | 0.736 | 267.0 (126.7–515.5) | 236.0 (141.3–395.5) | 0.261 |
|
| ||||||||
| Nodule size on CT, cm | 1.5 (1.3–1.6) | 1.5 (1.0–2.0) | 1.8 (1.4–2.3) | 1.5[ | 0..001 | 1.6 (1.3–2.0) | 1.5 (1.1–1.8) | 0.001 |
Values are expressed as median (interquartile range) or number (%).
PA, primary aldosteronism; PAC, plasma aldosterone concentration; CT, computed tomography; BMI, body mass index; BP, blood pressure; DDD, defined daily dose; eGFR, estimated glomerular filtration rate; PRA, plasma renin activity; ARR, aldosterone-to-renin ratio.
P<0.05, PA patients between ages <35 and 35–39 years with marked PA (e.g., hypokalemia and PAC >15.9 ng/dL) and unilateral adrenal lesion on CT;
P<0.05, PA patients between ages <40 and 40–49 years with marked PA (e.g., hypokalemia and PAC >15.9 ng/dL) and unilateral adrenal lesion on CT.